Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Merck makes circular RNA play with $3.5bn Orna alliance

On heels of new data, Gilead pays $455m for Asian Trodelvy rights

Roche eyes April FDA verdict on Polivy as first-line lymphoma therapy

Digital health’s rapid growth spurt comes home to roost

FDA grants swift review to Lynparza in first-line prostate cancer

Ferring Pharma

Bacteria-generic-3

News/ News/ R&D

PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy

Richard Staines C. diff infections, Ferring Pharma, infectious diseases, PureTech, R&D, Vedanta 0 Comment

US biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C.

X

PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy

https://pharmaphorum.com/news/puretechs-vedanta-biosciences-gets-federal-funding-for-c-diff-microbiome-therapy/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Novartis reports two liver-related deaths with Zolgensma
Enhertu role in breast cancer confirmed, as Daiichi wins Seagen dispute
Strike three for Novartis' canakinumab as lung cancer therapy
UK first to approve Moderna's Omicron booster jab
Survival data firms up Trodelvy prospects in new breast cancer use

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com